<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900610</url>
  </required_header>
  <id_info>
    <org_study_id>235/14.05.2021</org_study_id>
    <nct_id>NCT04900610</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis</brief_title>
  <acronym>VIKIPEDIA</acronym>
  <official_title>Vitamin K In PEritonial DIAlysis (VIKIPEDIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nattopharma ASA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VIKIPEDIA is a multi-centre, placebo-controlled, randomized, open-label intervention clinical&#xD;
      trial on Peritoneal Dialysis (PD) patients. At baseline the investigators will recruit&#xD;
      End-Stage Renal Disease patients undergoing PD and randomize them to either daily per os&#xD;
      supplementation of 1mg menaquinone-7 or placebo for 1.5 year. The investigators will study&#xD;
      the effect of vitamin K2 supplementation (through normalization of dp-ucMGP) on arterial&#xD;
      stifness and the occurence of cardiovascular events. The investigators will also cosider as&#xD;
      secondary endpoints, mortality, central aortic blood pressure and indices of 24h-ambulatory&#xD;
      blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VIKIPEDIA is a multi-centre, placebo-controlled, randomized, open-label intervention clinical&#xD;
      trial on PD patients. The study protocol was developed in accordance with the Helsinki&#xD;
      Declaration of Human Rights and the Good Clinical Practice Guidelines and Standard Protocol&#xD;
      Items: Recommendations for Intervention Trials, was approved by the Ethics&#xD;
      Committee/Scientific Council of the Medical School of Aristotle University of Thessaloniki&#xD;
      (235/14.05.2021) All participants will provide a structured, written, informed consent. Three&#xD;
      university, tertiary hospitals in Northern Greece with major, referral PD units will&#xD;
      participate in the study. The patients will be recruited within 1 year. At baseline, all&#xD;
      eligible patients who have provided a written, informed consent will be enrolled in the&#xD;
      study. Αortic stiffness and vitamin K status will be assessed by PWV and plasma dp-ucMGP&#xD;
      levels respectively. Before randomization, the investigators will draw blood (serum and&#xD;
      plasma) and PD fluid samples from all patients to measure blood count and routine biochemical&#xD;
      parameters, including urea, creatinine, potassium, sodium, calcium, phosphorus, c-reactive&#xD;
      protein, alkaline phosphatase, albumin, parathormone, 25-OH D3, magnesium, glycated&#xD;
      hemoglobin, thyroid function hormones. Since both vitamin D and magnesium are considered of&#xD;
      utmost importance in vitamin K metabolism, after baseline, patients with vitamin D and/or&#xD;
      magnesium depletion will be treated with oral supplements to achieve normal levels of both&#xD;
      elements, before randomization. The cohort will then be categorized to one of the two groups&#xD;
      (placebo or active group) and the treatment period will last 1.5 years. To ensure that the&#xD;
      two parallel groups will include patients that will not differ significantly in vitamin K and&#xD;
      stiffness, patients will be accordingly stratified. After randomization, all patients will&#xD;
      continue their routine, standard medical treatment and patients in the treatment group will&#xD;
      additionally receive daily, per os 1 mg of vitamin K2 (MenaQ7 ®, Nattopharma, ASA, Hovik,&#xD;
      Norway).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centre, placebo-controlled, randomized, open-label intervention clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of arterial stifness</measure>
    <time_frame>1.5 years</time_frame>
    <description>Change in pulse wave velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non fatal cardiovascular events</measure>
    <time_frame>1.5 years</time_frame>
    <description>Number of patients presenting acute myocardial infarction, acute coronary syndrome, embolism, peripheral arterial disease and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1.5 years</time_frame>
    <description>Number of participants who willl die from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD adequacy</measure>
    <time_frame>1.5 years</time_frame>
    <description>Number of patients with preserved residual renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD clearance</measure>
    <time_frame>1.5 years</time_frame>
    <description>Change in Kt/V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections/peritonitis</measure>
    <time_frame>1.5 years</time_frame>
    <description>Rate of infections and peritonitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathormone homeostasis</measure>
    <time_frame>1.5 year</time_frame>
    <description>Changes in serum parathormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium phosphorus homeostasis</measure>
    <time_frame>1.5 year</time_frame>
    <description>Changes in the calcium phosphorus product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures</measure>
    <time_frame>1.5 years</time_frame>
    <description>Incidence of fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint/muscle pain</measure>
    <time_frame>1.5 years</time_frame>
    <description>Incidence of pain in muscles and/or joints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour ambulatory BP/aortic systolic BP</measure>
    <time_frame>1.5 years</time_frame>
    <description>Change in indices of ambulatory BP and aortic systolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vitamin K Deficiency</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Peritoneal Dialysis</condition>
  <condition>Arterial Stiffness</condition>
  <condition>Cardiovascular Morbidity</condition>
  <condition>Mortality</condition>
  <arm_group>
    <arm_group_label>Vitamin K2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg/day per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MenaQ7 ®, Nattopharma, ASA, Hovik, Norway</intervention_name>
    <description>daily per os supplementation of 1mg MK-7</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin K2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  At least 3 months on PD&#xD;
&#xD;
          -  Life expectancy of ≥ 18 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Treatment with phosphate binders (sevelamer)&#xD;
&#xD;
          -  Ongoing malignancy or severe inflammatory disease diagnosis&#xD;
&#xD;
          -  Use of vitamin K antagonist or vitamin K supplements during the past 3 months&#xD;
&#xD;
          -  Diagnosis of severe gut-disease (inflammatory or short bowel disease) or&#xD;
             gastrointestinal malabsorption&#xD;
&#xD;
          -  Mental disorder rendering the patient unable to conform with the instructions and&#xD;
             fully understand the nature, aim and possible side-effects of the supplementation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefanos Roumeliotis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassilios Liakopoulos, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanos Roumeliotis, MD, PhD</last_name>
    <phone>+302313303110</phone>
    <email>st_roumeliotis@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vassilios Liakopoulos, Professor</last_name>
    <phone>+302313303110</phone>
    <email>liakopul@otenet.gr</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Vitamin K for the Treatment of Cardiovascular Disease in End-Stage Renal Disease Patients: Is there Hope? Curr Vasc Pharmacol. 2021;19(1):77-90. doi: 10.2174/1570161118666200320111745. Review.</citation>
    <PMID>32196451</PMID>
  </results_reference>
  <results_reference>
    <citation>Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review. Int J Mol Sci. 2019 Feb 1;20(3). pii: E628. doi: 10.3390/ijms20030628. Review.</citation>
    <PMID>30717170</PMID>
  </results_reference>
  <results_reference>
    <citation>Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein. Front Med (Lausanne). 2020 Apr 24;7:154. doi: 10.3389/fmed.2020.00154. eCollection 2020. Review.</citation>
    <PMID>32391368</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu Q, Guo H, Cao S, Zhou Q, Chen J, Su M, Chen S, Jiang S, Shi X, Wen Y. Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients. Int Urol Nephrol. 2019 Mar;51(3):527-534. doi: 10.1007/s11255-019-02080-x. Epub 2019 Jan 28.</citation>
    <PMID>30689181</PMID>
  </results_reference>
  <results_reference>
    <citation>Peeters FECM, van Mourik MJW, Meex SJR, Bucerius J, Schalla SM, Gerretsen SC, Mihl C, Dweck MR, Schurgers LJ, Wildberger JE, Crijns HJGM, Kietselaer BLJH. Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using (18)F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design. Nutrients. 2018 Mar 21;10(4). pii: E386. doi: 10.3390/nu10040386.</citation>
    <PMID>29561783</PMID>
  </results_reference>
  <results_reference>
    <citation>Haroon SW, Tai BC, Ling LH, Teo L, Davenport A, Schurgers L, Teo BW, Khatri P, Ong CC, Low S, Yeo XE, Tan JN, Subramanian S, Chua HR, Tan SY, Wong WK, Lau TW. Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK): A study protocol for a randomized controlled trial. Medicine (Baltimore). 2020 Sep 4;99(36):e21906. doi: 10.1097/MD.0000000000021906.</citation>
    <PMID>32899022</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaios V, Georgianos PI, Vareta G, Dounousi E, Dimitriadis C, Eleftheriadis T, Papagianni A, Zebekakis PE, Liakopoulos V. Clinic and Home Blood Pressure Monitoring for the Detection of Ambulatory Hypertension Among Patients on Peritoneal Dialysis. Hypertension. 2019 Oct;74(4):998-1004. doi: 10.1161/HYPERTENSIONAHA.119.13443. Epub 2019 Aug 12.</citation>
    <PMID>31401878</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Vaios Vasileios</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Menaquinone-7</keyword>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Arterial stifness</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Vitamin K Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

